Vacina contra o Papilomavírus Humano (HPV)

1. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis. Coordenação Geral do Programa Nacional de Imunizações. Informe técnico da vacina papilomavírus humano 6,11,16,18 (recombinante). Brasília;2015.

2. Commite on Infectious Diseases. HPV vaccine recommendations. American Academy of Paediatric. Paediatrics. 2012;129(3):603-5.

3. CDC. Quadrivalent human papillomavirus vaccine. Recommendations of the advisory committee on immunization practices (ACIP). MMWR. 2007; 56(RR-2):1-24.

4. Massad LS, Xie X, Darragh T, Minkoff H, Levine AM, Watts DH et al. Genital warts and vulvar intraepithelial neoplasia: natural history and effects of treatment and human immunodeficiency virus infection. Obstet. gynecol. 2011; 118(4):831-9.

5. Linda A, Robert SK, Robert B, Cu-Uvin S, Schuman P, Duerr A et al. Prevalence, incidence, and type-specific persistence of human Papillomavirus in Human Immunodeficiency Virus (HIV)–Positive and HIV-Negative Women. J. infect. dis. 2001;184:682-90.

6.Fruchter RG, Maiman M, Sedlis A, Bartley L, Camilien L, Arrastia CD. Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet. gynecol. 1996;87:338-44.

7. Moscicki AB, Ellenberg JH, Crowley-Nowick P, Darragh TM, Xu J, Fahrat S. Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents. J. infect. dis. 2004;190:1413-21.

8. Organização Mundial da Saúde. Weekly epidemiological record, Meeting of the Strategic Advisory Group of Experts on immunization, April 2014 – Conclusions and Recommendations No. 21, 2014, 89: 221–236

9. http://www.who.int/wer/2014/wer8921.pdf

10. US Public Health Service (USPHS). Infectious Diseases Society of America (IDSA). Guidelines for the Prevention of Opportunistic Infections with Human Immunodeficiency Virus: disease especific recommendations working group. USPHS/ IDSA Prevention of Opportunistic Infections Working Group. Clin. infect. dis. 1995; 21(Suppl 1):S32-43.

11. Milunka EK, Kang M, Cespedes MS, Umbleja T, Godfrey C, Allen RT, Firnhaber C et al.Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Women. Clin. infect. dis. 2014;59(1):127-135.

12. Kahn JA, Xu J, Kapogiannis BG et al. Immunogenicity and safety of human papillomavirus 6, 11, 16, 18 vaccine in HIV infected young women. Clin. infect. dis. 2013;57(5):735-744.

13. Wilkin T, Lee JY, Lensing SY et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J. infect. dis. 2010;202:1246-1253.

14. Levin MJ, Moscicki AB, Song L, Fenton T, Meyer WA, Read JS et al. Safety and immunogenicity of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) vaccine in HIV-Infected children 7 to 12 years old. J. acquir. immune defic. syndr. 2010;55(2):197-204.

15. Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere K et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomized placebo-controlled study. Vaccine. 2013;19;31(48):5745-53. doi:10.1016/ j. vaccine.2013.09.032.

16. Crawford NW, Clothier HJ, Elia S et al. Syncope and seizures following human papillomavirus vaccination: a retrospective case series. MJA . 2011;194(1) :16-18

17. Slade BA, Leidel L, Vellozzi C et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009; 302:750-7.

18. Dunne EE, Markowitz LE, Saraiya M et al. CDC grand rounds: reducing the burden of HPV-associated cancer and disease. MMWR. 2014;63(4):71-3.